Cargando…
Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
We evaluated disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in patients with stage I-III breast cancer with >4 MM/mL DTC at baseline who received adjuvant zoledronic acid (ZOL). ZOL was administered every 4 weeks for 24 months, and patients underwent bone marrow aspiration at...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421499/ https://www.ncbi.nlm.nih.gov/pubmed/34489453 http://dx.doi.org/10.1038/s41523-021-00323-8 |
_version_ | 1783749093595545600 |
---|---|
author | Vidula, Neelima Greenberg, Sally Petrillo, Laura Hwang, Jimmy Melisko, Michelle Goga, Andrei Moasser, Mark Magbanua, Mark Park, John W. Rugo, Hope S. |
author_facet | Vidula, Neelima Greenberg, Sally Petrillo, Laura Hwang, Jimmy Melisko, Michelle Goga, Andrei Moasser, Mark Magbanua, Mark Park, John W. Rugo, Hope S. |
author_sort | Vidula, Neelima |
collection | PubMed |
description | We evaluated disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in patients with stage I-III breast cancer with >4 MM/mL DTC at baseline who received adjuvant zoledronic acid (ZOL). ZOL was administered every 4 weeks for 24 months, and patients underwent bone marrow aspiration at baseline, and 12 and 24 months of ZOL. Complete DTC response (<4 DTC/mL), serial CTCs, survival, recurrence, and toxicity were determined. Forty-five patients received ZOL. Median baseline DTC was 13.3/mL. Significant reduction in median DTC occurred from baseline to 12 months, and 24 months. Complete DTC response was seen in 32% at 12 months, and 26% at 24 months. Nine patients developed recurrence. Baseline DTC > 30/mL and CTC > 0.8/mL were significantly associated with recurrence and death. Serial reduction in DTCs occurred. Higher baseline DTC > 30/mL and CTC > 0.8/mL correlated with recurrence and death. |
format | Online Article Text |
id | pubmed-8421499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84214992021-09-14 Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid Vidula, Neelima Greenberg, Sally Petrillo, Laura Hwang, Jimmy Melisko, Michelle Goga, Andrei Moasser, Mark Magbanua, Mark Park, John W. Rugo, Hope S. NPJ Breast Cancer Article We evaluated disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in patients with stage I-III breast cancer with >4 MM/mL DTC at baseline who received adjuvant zoledronic acid (ZOL). ZOL was administered every 4 weeks for 24 months, and patients underwent bone marrow aspiration at baseline, and 12 and 24 months of ZOL. Complete DTC response (<4 DTC/mL), serial CTCs, survival, recurrence, and toxicity were determined. Forty-five patients received ZOL. Median baseline DTC was 13.3/mL. Significant reduction in median DTC occurred from baseline to 12 months, and 24 months. Complete DTC response was seen in 32% at 12 months, and 26% at 24 months. Nine patients developed recurrence. Baseline DTC > 30/mL and CTC > 0.8/mL were significantly associated with recurrence and death. Serial reduction in DTCs occurred. Higher baseline DTC > 30/mL and CTC > 0.8/mL correlated with recurrence and death. Nature Publishing Group UK 2021-09-06 /pmc/articles/PMC8421499/ /pubmed/34489453 http://dx.doi.org/10.1038/s41523-021-00323-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Vidula, Neelima Greenberg, Sally Petrillo, Laura Hwang, Jimmy Melisko, Michelle Goga, Andrei Moasser, Mark Magbanua, Mark Park, John W. Rugo, Hope S. Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid |
title | Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid |
title_full | Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid |
title_fullStr | Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid |
title_full_unstemmed | Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid |
title_short | Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid |
title_sort | evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421499/ https://www.ncbi.nlm.nih.gov/pubmed/34489453 http://dx.doi.org/10.1038/s41523-021-00323-8 |
work_keys_str_mv | AT vidulaneelima evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT greenbergsally evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT petrillolaura evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT hwangjimmy evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT meliskomichelle evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT gogaandrei evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT moassermark evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT magbanuamark evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT parkjohnw evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid AT rugohopes evaluationofdisseminatedtumorcellsandcirculatingtumorcellsinpatientswithbreastcancerreceivingadjuvantzoledronicacid |